2000
Defining CD95 as a tumor suppressor gene
Müschen M, Warskulat U, Beckmann M. Defining CD95 as a tumor suppressor gene. Journal Of Molecular Medicine 2000, 78: 312-325. PMID: 11001528, DOI: 10.1007/s001090000112.Peer-Reviewed Original ResearchConceptsTumor suppressor geneSuppressor geneCD95L expressionReceptor-ligand systemCD95L-mediated apoptosisKey regulatorDe novo expressionMalignant cellsGenesSomatic mutationsCD95 geneLymphocyte homeostasisBystander cellsCD95ApoptosisNatural ligandMalignant progressionNonmalignant counterpartsNovo expressionTumor progressionExpressionCellsTumor cellsGermlineAntitumor immunityCD95 ligand expression as a mechanism of immune escape in breast cancer
Müschen M, Moers C, Warskulat U, Even J, Niederacher D, Beckmann M. CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology 2000, 99: 69-77. PMID: 10651943, PMCID: PMC2327134, DOI: 10.1046/j.1365-2567.2000.00921.x.Peer-Reviewed Original ResearchMeSH KeywordsApoptosisBreast NeoplasmsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesEnzyme-Linked Immunosorbent AssayFas Ligand ProteinFas ReceptorFemaleFlow CytometryHumansImmunohistochemistryJurkat CellsLymphocyte CountMembrane GlycoproteinsProtein IsoformsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerConceptsBreast cancer cellsT cellsBreast cancerCD95L expressionImmune escapeIFN-gammaCancer cellsJurkat T cellsTumor-infiltrating T cellsCD95L mRNA levelsDepletion of CD4Cultured breast cancer cellsBreast cancer patientsPeripheral blood lymphocytesCD95/CD95L systemBreast cancer cell linesNon-malignant mammary tissuesActivated T cellsCD95 ligand expressionRate of apoptosisBreast cancer sectionsCancer cell linesInteraction of CD95Systemic immunosuppressionCancer patients
1999
Regulation of CD95 (APO‐1/ FAS) ligand and receptor expression in squamous‐cell carcinoma by interferon‐γ and cisplatin
Moers C, Warskulat U, Müschen M, Even J, Niederacher D, Josien R, Koldovsky U, Beckmann M, Häussinger D. Regulation of CD95 (APO‐1/ FAS) ligand and receptor expression in squamous‐cell carcinoma by interferon‐γ and cisplatin. International Journal Of Cancer 1999, 80: 564-572. PMID: 9935158, DOI: 10.1002/(sici)1097-0215(19990209)80:4<564::aid-ijc14>3.0.co;2-x.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaExpression of CD95LPrimary cell linesPrimary squamous cell carcinomaStroma cellsCD95L expressionAddition of CDDPCD95L mRNA levelsTumor-associated immunosuppressionHuman primary cell linesMRNA levelsEffect of cisplatinCell linesCD95 ligand expressionInvasive tumor tissuesAutologous lymphocytesCell carcinomaReceptor expressionSCC cellsSoluble receptorLigand expressionTumor tissueTumor samplesReceptor isoformsInvasion factors
1998
Regulation of CD95 (APO‐1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells
Müschen M, Warskulat U, Douillard P, Gilbert E, Häussinger D. Regulation of CD95 (APO‐1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells. Hepatology 1998, 27: 200-208. PMID: 9425938, DOI: 10.1002/hep.510270131.Peer-Reviewed Original ResearchConceptsSinusoidal endothelial cellsNumber of KCsCD95L mRNA levelsKupffer cellsParenchymal cellsMRNA levelsNonparenchymal rat liver cellsNonparenchymal cellsCD95L expressionEffects of lipopolysaccharideMeans of immunocytochemistryLiver Kupffer cellsAddition of supernatantsPresence of lipopolysaccharideLiver cell populationsRat liver Kupffer cellsMessenger RNA levelsCD95 receptorLPS treatmentRat liver cellsThymic lymphocytesCD95 expressionLigand expressionLPS additionPrimary hepatocyte cultures